Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00647335 · ClinicalTrials.gov registry record

Genetics of Polycystic Ovary Syndrome

A clinical trial, sponsored by University of Pennsylvania.

Completed
Registry status
189
Enrollment target

NCT00647335: Completed study, sponsored by University of Pennsylvania.

NCT00647335 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 189 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00647335 has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
189 participants
Enrollment target

Study Summary

The purpose of this study is to look at genes (DNA) and how they affect health and disease. Genes are the instruction manual for the body. The genes you get from your parents decide what you look like and how your body behaves. They can also tell us a person's risk for certain diseases and how they will respond to treatment. We will collect a saliva sample for genetic research.

Trial Details

FieldValue
Enrollment Target 189 participants
Start Date 2008-02
Est. Completion 2012-01
University of Pennsylvania

1,423 total trials

What the finished NCT00647335 record still lists

NCT00647335 is an observational study that tracks outcomes without assigning an intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00647335 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00647335 about?

NCT00647335 is a clinical study titled "Genetics of Polycystic Ovary Syndrome". The purpose of this study is to look at genes (DNA) and how they affect health and disease. Genes are the instruction manual for the body. The genes you get from your parents decide what you look like and how your body behaves. They can also tell us a person's risk for certain diseases and how they ...

What is the current status of trial NCT00647335?

This trial is currently completed. The enrollment target is 189 participants. The study started on 2008-02. Estimated completion is 2012-01.

Who is sponsoring clinical trial NCT00647335?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02734537 · 189 participants · Phase 2

    Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  • NCT05058651 · 189 participants · Phase 2

    Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

  • NCT05673408 · 189 participants

    NIBP Validation Study

  • NCT05994209 · 189 participants · Phase 1

    Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00647335, the US trial registry maintained by the National Library of Medicine. NCT00647335 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.